We have a team of experts with incredible knowledge and experience in a variety of backgrounds.
Board and Executive Management
Bionxt’s board and executive management bring significant expertise in science, therapeutics, business development and growth. Combine the collective skills of the team with an entrepreneurial eye for opportunity and you can see why Bionxt is poised to be a disrupter in the pharmaceutical industry.
Hugh Rogers
Mr. Rogers is an entrepreneur and lawyer with private and public start-up experience in a range of industries and operational roles.
Recent advisory work has focused on public listings and corporate restructuring in the life science (cell therapy and medical device) and natural resource (natural gas co-gen and conventional oil) industries. Mr. Rogers has held several board and executive management positions with junior exchange listed issuers. He holds a bachelor’s degree in Cell Biology and Genetics and a Law degree. He is a member in good standing of the Law Society of British Columbia.
Prof. Dr. Thomas Beckert
Prof. Dr. Beckert is the founder, managing director, and qualified person of Vektor Pharma TF GmbH, Uttenweiler, Germany, and managing director of XP Diagnostics. He further is managing director of SCUR alpha 1108 GmbH, Bionxt’s holding company for the German operations.
Besides company organization, his expertise includes formulation and machine development for transdermal therapeutic systems and ODFs, narcotic drugs, cannabis, and herbal extracts in addition to global auditing of pharmaceutical suppliers (including cGMP, GDP, GACP, API, transdermals, solids, sterile dosage forms, analytical labs, microbiological labs, and pharmacovigilance).
Prof. Dr. Beckert passed his pharmaceutical state examination at the University of Freiburg, Freiburg im Breisgau, Germany in 1991, and holds a Ph.D. in Pharmacy from the University of Tübingen, Tübingen, Germany.
He was appointed professor of Pharmaceutical Process Technologies, University of Applied Sciences, Albstadt-Sigmaringen in 2020. From 1996 – 2009 he took the responsibility as a global technical customer advisor for EVONIK’s EUDRAGIT® product range for controlled drug delivery and was member of the board at Acino AG and Rentschler Pharma GmbH.
Dr. Florian A. Sahr
Dr. Sahr is a German-born and internationally trained leader in drug formulation, technology transfer and new-product manufacturing.
Dr. Sahr has a strong track record of drug development, including transdermal (“TDS”) and oral dissolvable (“ODF”) delivery systems, as well as the physical and regulatory establishment of GMP and FDA compliant pharmaceutical manufacturing facilities.
Several employment highlights include his work as Senior Scientist, Head of Manufacturing, Gen-Plus GmbH & Co. KG, Munich, Germany, where he developed TDS and ODF drug formulations and transferred these new formulations and technologies to manufacturing systems and facilities; and his work as Project Manager, Advanced Projects, tesa Labtec GmbH, Langenfeld, Germany, focusing on project management and technology transfer of generic TDS formulations to the company’s manufacturing facilities.
Dr. Sahr has held the regulated position of Head of Manufacturing according to AMG/AMWHV (German Medicines Act) for the production of clinical trial materials for a number of companies.
Roland Spleiss
Mr. Roland Spleiss has joined as the Director of Business Development. Mr. Spleiss is a seasoned commercial professional with over 25 years of experience in planning and building out effective salesforces, strategic realignment, production relocation, and project management, which makes him ideally suited to drive product sales.
In addition to extensive consulting roles, Mr. Spleiss held senior positions including Chief Financial Officer of Wörwag Pharma, a private German health and generic pharmaceutical company with over EUR 200 million in annual sales and 900 employees. He led the company’s strategic professionalization and internationalization of operations, optimization of supply chains and sales processes, and expansion into new European, Asian and Latin American healthcare markets.
Mr. Spleiss’ expertise in production and supply chain management, cost optimization, and sales force and distribution network creation will be invaluable to Bionxt’s commercial strategy and execution.
Dr. Heinrich Jehle
Dr. Heinrich Jehle has joined Bionxt as Head of Diagnostic Research. Dr. Jehle has over 20 years’ experience in the research and development of innovative medical screening tests and diagnostics. Previously, Dr. Jehle held senior roles in project management and research & development at leading European biotech and diagnostics companies.
More recently, Dr. Jehle co-founded 3a-diagnostics GmbH as managing director where he led the development of the first saliva activated “in-mouth” biosensor candidates to identify active pathogens in the saliva and built a portfolio of innovative diagnostics biosensor products. The enzyme-activated biosensors are developed for real-time, low-cost and easy-to-use oral screening applications for the rapid detection of infectious diseases including COVID-19 at home or at the point-of-care.
Joseph Meagher
Chartered Professional Accountant (CPA, CA) since 2008, obtained the Chartered Director (C.Dir.) designation from The Directors College (a joint venture between McMaster University and The Conference Board of Canada) in 2017. Joseph currently serves as the CFO for several publicly listed companies.
Per Thoresen
Mr. Thoresen is an experienced leader with an impressive track record in a wide range of executive management roles in the pharmaceutical industry. He has 25 years’ experience including executive roles with major international European and Asian-based pharmaceutical companies and has more recently led a number of successful ventures in the pharmaceutical manufacturing, nutraceutical and other industry sectors. From 2003 to 2014, Mr. Thoresen was the managing director of Nycomed Pharma AS acquired by Takeda Pharmaceutical Company Limited in 2011 as part of an acquisition transaction with a total value of approximately USD $14B.
Mr. Thoresen holds a law degree from the top-ranked University of Oslo and core competencies in strategy and organizational development, operational execution, and industry and government relations. He is an experienced chairman and board member of numerous European industry associations and companies and is the co-founder and current chairman of Curida AS, a Norwegian-based contract development manufacturing organization focused on liquid pharmaceutical production.
Prof. Dr. Raimar Löbenberg
Dr. Löbenberg holds a bachelor’s of Science degree in Pharmacy from the Johannes Gutenberg-University, Mainz, Germany and a PhD in Pharmaceutics from the Johann Wolfgang Goethe-University, Frankfurt, Germany. He joined the University of Alberta in 2000 where he is the founder and director of the Drug Development and Innovation Centre, Faculty of Pharmacy and Pharmaceutical Sciences. Dr. Löbenberg’s research interests are in biopharmaceutics to predict the oral performance of drugs and botanicals and inhalable nanoparticles to treat lung diseases such as lung cancer, tuberculosis or leishmanasis. He is a cofounder of RS Therapeutics Inc., a foam-based topical drug delivery company.
Dr. Löbenberg’s recent notable positions include: president of the Canadian Society for Pharmaceutical Sciences 2014 to 2015; vice chair of the United States Pharmacopeia Dietary Supplement Expert Committee 2016 to 2017; current member of the United States Pharmacopeia Dietary Supplement Expert Committee; current vice chair of the Specialty Committee of Traditional Chinese Medicine in Pharmaceutics of the World Foundation of Chinese Medicine Science; and current member of the Health Canada Scientific Advisory Committee on Pharmaceutical Sciences and Clinical Pharmacology and the Scientific Advisory Panel on Opioid Analgesic Abuse.
Wolfgang Probst
Mr. Probst is an experienced management consultant specialized in investment consulting and capitalization.
He’s an expert in mergers and acquisitions, corporate re-organizations, and divestitures and has adroitly brought multiple startups to success. Owing to his superior negotiating skills, he has a proven track record in strategic analysis, which resulted in highly targeted organizational restructuring.
Peter Damouni
Mr. Damouni is an entrepreneur and financier with over 18 years of experience in investment banking and capital markets including more than 10 years as a director or an officer of a number of private and public companies listed on the TSX, the TSXV and LSE.
Throughout his career, Mr. Damouni has taken a lead role in equity and debt financings.
His expertise on financing, restructuring, strategy development and execution, mergers and acquisitions has been instrumental in creating significant value for shareholders in the consumer, natural resources, technology and life sciences sectors.
“We have ambitious milestones for Bionxt’s future, and I am confident our team will execute.”
– Hugh Rogers, CEO
Invest in Bionxt, invest in innovation
Learn more about Bionxt’s innovation to impact strategy and get access to Bionxt investor information.
CSE:BNXT FSE:4XT OTCQB:XPHYF